Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

Catalyst Flex, a functional service provider (FSP) solution of Catalyst Clinical Research, is a multi-therapeutic niche contract research organization (CRO)with flexible, fit-for-purpose offerings in ...

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.

Mental health has become one of the significant factors determining early retirement, disability benefits, absenteeism levels, and high societal costs such as productivity losses and medical treatment ...

We asked John Oyler, an American entrepreneur and the chairman, cofounder, and CEO of BeiGene, why he decided to build a global biopharmaceutical company with roots beginning in China. His answer may ...

Matt Patterson, chairman and CEO of Audentes Therapeutics, shares the experiences that prepared him for building the gene therapy company he cofounded into a publicly traded business valued at nearly ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

When should a brand become two brands? Charles River Associates provide analyses and case studies of dual brands to elucidate the pros and cons.

Pharma companies can benefit from conducting war games by gaining a better understanding of the external opportunities and challenges of all the key stakeholders in the industry.